Rheumatoid Arthritis Drugs Market Analysis: Major Players, Lucrative Segments And Top Geographies
19 Jun, 2023
The global rheumatoid arthritis market size is expected to grow from $60.61 billion in 2022 to $60.82 billion in 2023 at a compound annual growth rate (CAGR) of 0.34%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global rheumatoid arthritis market size is expected to reach $63.26 billion in 2027 at a CAGR of 0.99%.
Global Rheumatoid Arthritis Drugs Market Key Driver
The growing number of arthritis cases is predicted to boost the rheumatoid arthritis medications industry ahead. Rheumatoid arthritis is an autoimmune and inflammatory disorder in which the immune system intentionally destroys healthy cells in the body, causing inflammation (painful swelling) in the affected areas. Rheumatoid arthritis medications and self-management approaches are widely available to effectively treat RA. The medications alleviate pain, improve joint flexibility, and prevent illness transmission.
Get a sample of the global rheumatoid arthritis drugs market reportGlobal Rheumatoid Arthritis Drugs Market Segments
The global rheumatoid arthritis drugs market is segmented:
1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic Response Modifiers (BRMs), Other Drug Types
2) By Route Of Administration: Oral, Parenteral, Topical, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By Geography: The regions covered in the rheumatoid arthritis drugs market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global rheumatoid arthritis drugs market.
Major Rheumatoid Arthritis Drugs Industry Players
Pfizer Inc., Abbvie Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, F-Hoffmann La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Merck & Co Inc., Johnson & Johnson Inc., Bayer AG, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A
Get the full global rheumatoid arthritis drugs market report
Rheumatoid Arthritis Drugs Market Overview
Rheumatoid arthritis drugs refer to drugs given for the treatment of an autoimmune disease, which has symptoms like inflammation of the tissues around the joints. These medications minimize permanent harm to the joints and other tissues while slowing the progression of rheumatoid arthritis.
Rheumatoid Arthritis Drugs Global Market Report 2023 provides data on the global rheumatoid arthritis drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The rheumatoid arthritis drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.